GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pulmonx Corp (NAS:LUNG) » Definitions » Beneish M-Score

Pulmonx (Pulmonx) Beneish M-Score : -2.74 (As of Apr. 28, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Pulmonx Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.74 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Pulmonx's Beneish M-Score or its related term are showing as below:

LUNG' s Beneish M-Score Range Over the Past 10 Years
Min: -2.74   Med: -2.56   Max: -0.77
Current: -2.74

During the past 6 years, the highest Beneish M-Score of Pulmonx was -0.77. The lowest was -2.74. And the median was -2.56.


Pulmonx Beneish M-Score Historical Data

The historical data trend for Pulmonx's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pulmonx Beneish M-Score Chart

Pulmonx Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial - - -0.77 -2.56 -2.74

Pulmonx Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.56 -2.80 -2.23 -1.64 -2.74

Competitive Comparison of Pulmonx's Beneish M-Score

For the Medical Devices subindustry, Pulmonx's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pulmonx's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pulmonx's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Pulmonx's Beneish M-Score falls into.



Pulmonx Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Pulmonx for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0964+0.528 * 1.0052+0.404 * 1.5262+0.892 * 1.2798+0.115 * 0.7308
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.8895+4.679 * -0.126898-0.327 * 1.6338
=-2.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $13.02 Mil.
Revenue was 19.278 + 17.668 + 17.194 + 14.535 = $68.68 Mil.
Gross Profit was 14.4 + 13.029 + 12.734 + 10.589 = $50.75 Mil.
Total Current Assets was $150.42 Mil.
Total Assets was $177.78 Mil.
Property, Plant and Equipment(Net PPE) was $7.43 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.55 Mil.
Selling, General, & Admin. Expense(SGA) was $94.61 Mil.
Total Current Liabilities was $23.16 Mil.
Long-Term Debt & Capital Lease Obligation was $36.20 Mil.
Net Income was -13.888 + -14.9 + -16.195 + -15.86 = $-60.84 Mil.
Non Operating Income was -0.357 + -0.262 + -0.162 + 0.108 = $-0.67 Mil.
Cash Flow from Operations was -8.449 + -8.626 + -7.891 + -12.644 = $-37.61 Mil.
Total Receivables was $9.28 Mil.
Revenue was 15.425 + 13.502 + 13.95 + 10.785 = $53.66 Mil.
Gross Profit was 11.184 + 10.152 + 10.418 + 8.111 = $39.87 Mil.
Total Current Assets was $168.95 Mil.
Total Assets was $193.68 Mil.
Property, Plant and Equipment(Net PPE) was $10.50 Mil.
Depreciation, Depletion and Amortization(DDA) was $1.51 Mil.
Selling, General, & Admin. Expense(SGA) was $83.11 Mil.
Total Current Liabilities was $18.49 Mil.
Long-Term Debt & Capital Lease Obligation was $21.08 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(13.02 / 68.675) / (9.279 / 53.662)
=0.189589 / 0.172916
=1.0964

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(39.865 / 53.662) / (50.752 / 68.675)
=0.742891 / 0.739017
=1.0052

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (150.422 + 7.434) / 177.781) / (1 - (168.953 + 10.5) / 193.676)
=0.112076 / 0.073437
=1.5262

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=68.675 / 53.662
=1.2798

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1.513 / (1.513 + 10.5)) / (1.548 / (1.548 + 7.434))
=0.125947 / 0.172345
=0.7308

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(94.607 / 68.675) / (83.105 / 53.662)
=1.377605 / 1.548675
=0.8895

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((36.195 + 23.157) / 177.781) / ((21.083 + 18.492) / 193.676)
=0.333849 / 0.204336
=1.6338

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-60.843 - -0.673 - -37.61) / 177.781
=-0.126898

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Pulmonx has a M-score of -2.74 suggests that the company is unlikely to be a manipulator.


Pulmonx Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Pulmonx's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Pulmonx (Pulmonx) Business Description

Traded in Other Exchanges
Address
700 Chesapeake Drive, Redwood, CA, USA, 94063
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). the company's solutions comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the U.S. and international markets.
Executives
French Glendon E. Iii director, officer: President and CEO 700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Geoffrey Beran Rose officer: Chief Commercial Officer 5124 ROCKWOOD PARKWAY NW, WASHINGTON DC 20016
John Mckune officer: Interim CFO 46668 CRAWFORD CT., FREMONT CA 94539
David Aaron Lehman officer: General Counsel C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Derrick Sung officer: Chief Financial Officer C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 380, SAN FRANCISCO CA 94103
Alissa Hsu Lynch director 700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Richard M Ferrari director 2118 WALSH AVENUE, SUITE 210, SANTA CLARA CA 95050
Tiffany Sullivan director 700 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Boston Scientific Corp 10 percent owner 300 BOSTON SCIENTIFIC WAY, MARLBOROUGH MA 01752-1234
Daniel P Florin director 56 E. BELL DRIVE, WARSAW IN 46581
Mead Dana G Jr. director 2750 SAND HILL ROAD, MENLO PARK CA 94025
Thomas William Burns director C/O GLAUKOS CORPORATION,, 26051 MERIT CIRCLE, SUITE 103, LAGUNA HILLS CA 92653
Georgia Melenikiotou director C/O INSPIRE MEDICAL SYSTEMS, INC., 5500 WAYZATA BOULEVARD, SUITE 1600, GOLDEN VALLEY MN 55416
Staffan Lindstrand director C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51

Pulmonx (Pulmonx) Headlines